{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:10:08Z","timestamp":1778789408291,"version":"3.51.4"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"vor","delay-in-days":4878,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2002,8]]},"DOI":"10.1046\/j.1523-1755.2002.00450.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T09:50:15Z","timestamp":1047462615000},"page":"367-374","source":"Crossref","is-referenced-by-count":52,"title":["Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure"],"prefix":"10.1016","volume":"62","author":[{"given":"Hartmut H.","family":"Malluche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Mawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Koszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1046\/j.1523-1755.2002.00450.x_bb0010","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/ajkd.1998.v32.pm9808141","article-title":"Vitamin D analogues","volume":"32","author":"Brown","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0015","first-page":"F157","article-title":"Vitamin D","volume":"277","author":"Brown","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0020","first-page":"765","article-title":"Clinical counterpoint: Vitamin D: new actions, new analogs, new therapeutic potential","volume":"13","author":"Bikle","year":"1992","journal-title":"Endocr Rev"},{"issue":"Suppl","key":"10.1046\/j.1523-1755.2002.00450.x_bb0025","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/ajkd.1998.v32.pm9808140","article-title":"Mechanism of vitamin D action and its regulation","volume":"32","author":"Dusso","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ndt\/11.supp3.153","article-title":"1 alpha-Hydroxy-vitamin D2: A new look at an \u2018old\u2019 compound","volume":"11","author":"Coburn","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: The second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1359\/jbmr.1998.13.3.325","article-title":"The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed","volume":"13","author":"Haussler","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1677\/jme.0.0160183","article-title":"Novel and sensitive detection systems for the vitamin D receptor\u2014in situ-reverse transcriptase-polymerase chain reaction and immunogold cytochemistry","volume":"16","author":"Mee","year":"1996","journal-title":"J Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0006-291X(91)91234-4","article-title":"Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rat","volume":"181","author":"Sandgren","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1097-2765(00)80413-X","article-title":"The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand","volume":"5","author":"Rochel","year":"2000","journal-title":"Mol Cell"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0060","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.020522697","article-title":"Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain","volume":"97","author":"Yamamoto","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-1119(00)00052-4","article-title":"Mechanisms of gene regulation by vitamin D(3) receptor: A network of coactivator interactions","volume":"246","author":"Rachez","year":"2000","journal-title":"Gene"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1006\/bbrc.1998.9799","article-title":"The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators","volume":"253","author":"Tagami","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1677\/jme.0.0200327","article-title":"Repression of basal transcription by vitamin D receptor: evidence for interaction of unliganded vitamin D receptor with two receptor interaction domains in RIP13delta1","volume":"20","author":"Dwivedi","year":"1998","journal-title":"J Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0080","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1073\/pnas.92.5.1535","article-title":"Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription","volume":"92","author":"Blanco","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0085","doi-asserted-by":"crossref","first-page":"16434","DOI":"10.1074\/jbc.273.26.16434","article-title":"Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription","volume":"273","author":"Baudino","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/mend.12.1.0048","article-title":"Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1","volume":"12","author":"Gill","year":"1998","journal-title":"Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0095","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1006\/bbrc.1999.2044","article-title":"Biochemical evidence for a 170-kilodalton, AF-2-dependent vitamin D receptor\/retinoid X receptor coactivator that is highly expressed in osteoblasts","volume":"267","author":"Jurutka","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1101\/gad.12.12.1787","article-title":"A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system","volume":"12","author":"Rachez","year":"1998","journal-title":"Genes Dev"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0959-437X(99)80021-5","article-title":"Coactivator and corepressor complexes in nuclear receptor function","volume":"9","author":"Xu","year":"1999","journal-title":"Curr Opin Genet Dev"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1006\/bbrc.1996.1665","article-title":"Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene","volume":"228","author":"Hawa","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0115","first-page":"298","article-title":"Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor","volume":"10","author":"Mackey","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0120","first-page":"206","article-title":"Characterization of a response element in the 5\u2032-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor","volume":"10","author":"Liu","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0125","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/jbmr.5650111203","article-title":"Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis","volume":"11","author":"Cooper","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/hmg\/2.4.487","article-title":"ApaI, BsmI, EcoRV and TaqI polymorphisms at the human vitamin D receptor gene locus in Caucasians, blacks and Asians","volume":"2","author":"Hustmyer","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0135","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1046\/j.1523-1755.1999.00678.x","article-title":"Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients","volume":"56","author":"Marco","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/ajcp\/112.3.366","article-title":"BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients","volume":"112","author":"Tagliabue","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/ajkd.1998.v32.pm9740163","article-title":"Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients","volume":"32","author":"Nagaba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0150","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1681\/ASN.V8101546","article-title":"Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure","volume":"8","author":"Fernandez","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0155","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/jbmr.5650111204","article-title":"The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women","volume":"11","author":"Gross","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/mend.14.3.0435","article-title":"The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB","volume":"14","author":"Jurutka","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ndt\/11.supp3.130","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"11","author":"Slatopolsky","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0170","first-page":"267","article-title":"Understanding and managing hyperphosphatemia in patients with chronic renal disease","volume":"52","author":"Malluche","year":"1999","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"10.1046\/j.1523-1755.2002.00450.x_bb0175","first-page":"S38","article-title":"Renal bone disease\u2013an ongoing challenge to the nephrologist","volume":"44","author":"Malluche","year":"1995","journal-title":"Clin Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1990.187","article-title":"Renal bone disease 1990: An unmet challenge for the nephrologist","volume":"38","author":"Malluche","year":"1990","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0185","first-page":"309","article-title":"Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow","volume":"54","author":"Malluche","year":"2000","journal-title":"Clin Nephrol"},{"issue":"Suppl 73","key":"10.1046\/j.1523-1755.2002.00450.x_bb0190","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1046\/j.1523-1755.1999.07307.x","article-title":"What is the optimal regimen for vitamin D?","volume":"56","author":"Cunningham","year":"1999","journal-title":"Kidney Int"},{"issue":"Suppl 73","key":"10.1046\/j.1523-1755.2002.00450.x_bb0195","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"56","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0200","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1210\/endo-119-3-1298","article-title":"1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs","volume":"119","author":"Malluche","year":"1986","journal-title":"Endocrinology"},{"issue":"Suppl","key":"10.1046\/j.1523-1755.2002.00450.x_bb0205","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1007\/BF03194369","article-title":"Pathogenesis and histology of renal osteodystrophy","volume":"7","author":"Malluche","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0210","series-title":"Clinical Dialysis, 3rd ed","first-page":"744","article-title":"Parathyroid hormone, vitamin D, and metabolic bone disease in dialysis patients,","author":"Sawaya","year":"1995"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0215","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0225","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1525-1594.1998.06198.x","article-title":"Renal osteodystrophy in dialysis patients: Diagnosis and treatment","volume":"22","author":"Fournier","year":"1998","journal-title":"Artif Organs"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbmr.5650100121","article-title":"Risk factors for renal osteodystrophy: A multivariant analysis","volume":"10","author":"Pei","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0235","first-page":"62","article-title":"Risk of adynamic bone disease in dialyzed patients","volume":"42","author":"Malluche","year":"1992","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0272-6386(95)90599-5","article-title":"Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis","volume":"26","author":"Qi","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0245","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.1994.342","article-title":"Evidence for abnormal calcium homeostasis in patients with adynamic bone disease","volume":"46","author":"Kurz","year":"1994","journal-title":"Kidney Int"},{"issue":"Suppl 73","key":"10.1046\/j.1523-1755.2002.00450.x_bb0250","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1046\/j.1523-1755.1999.07313.x","article-title":"The role of bone biopsy in clinical practice and research","volume":"56","author":"Malluche","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0255","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jcem.84.11.6236","article-title":"A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure","volume":"84","author":"John","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0260","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","article-title":"Improved assessment of bone turnover by the PTH-(1-84)\/large C-PTH fragments ratio in ESRD patients","volume":"60","author":"Monier-Faugere","year":"2001","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0265","first-page":"E1108","article-title":"1,25(OH)2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes","volume":"268","author":"Wu","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0272-6386(99)70260-X","article-title":"Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism","volume":"33","author":"Park","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0275","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0272-6386(97)90459-5","article-title":"Hyperparathyroidism in the hemodialysis population: A survey of 612 patients","volume":"29","author":"Salem","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0280","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1523-1755.1999.00575.x","article-title":"Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure","volume":"56","author":"Rostand","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0285","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0290","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90484-4","article-title":"Effects of excess PTH on nonclassical target organs","volume":"30","author":"Bro","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0295","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia","volume":"328","author":"Rao","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0300","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI117890","article-title":"Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia","volume":"95","author":"Arnold","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0305","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0310","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0315","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/ndt\/13.5.1234","article-title":"Safety and efficacy of pulse and daily calcitriol in patients on CAPD: A randomized trial","volume":"13","author":"Moe","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0320","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(12)80831-6","article-title":"Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol","volume":"19","author":"Sprague","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0325","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1681\/ASN.V73488","article-title":"Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients","volume":"7","author":"Levine","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0330","first-page":"122","article-title":"Intravenous versus oral calcitriol therapy in renal osteodystrophy: Results of a prospective, pulsed and dose-comparable study","volume":"20","author":"Mazzaferro","year":"1994","journal-title":"Miner Electrolyte Metab"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0335","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","article-title":"Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration","volume":"54","author":"Salusky","year":"1998","journal-title":"Kidney Int"},{"issue":"Suppl 73","key":"10.1046\/j.1523-1755.2002.00450.x_bb0340","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1046\/j.1523-1755.1999.07316.x","article-title":"Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences","volume":"56","author":"Llach","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0345","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1681\/ASN.V251014","article-title":"The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients","volume":"2","author":"Rodriguez","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0002-9629(15)40516-6","article-title":"Update on renal osteodystrophy: Pathogenesis and clinical management","volume":"317","author":"Sakhaee","year":"1999","journal-title":"Am J Med Sci"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ndt\/8.6.530","article-title":"Calcium carbonate (CaCO3): An efficient and safe phosphate binder in haemodialysis patients? A 3-year study","volume":"8","author":"Sperschneider","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0360","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ndt\/13.suppl_3.57","article-title":"The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure","volume":"13","author":"Llach","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0370","first-page":"767","article-title":"Toward a new treatment paradigm for hyperphosphatemia in chronic renal disease","volume":"27","author":"Norris","year":"1998","journal-title":"Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0375","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0272-6386(96)90363-7","article-title":"Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients","volume":"27","author":"Braun","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0380","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/ndt\/14.9.2178","article-title":"Asssociation of hyperphosphataemia with haemodynamic disturbances in ESRD","volume":"14","author":"Marchais","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0385","first-page":"2000","article-title":"Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism","volume":"85","author":"Carling","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0390","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0272-6386(96)90473-4","article-title":"Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure","volume":"28","author":"Denda","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0395","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0400","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000045373","article-title":"Hyperphosphatemia: A serious limiting factor preventing the possible benefit from intravenous calcitriol therapy","volume":"82","author":"Arik","year":"1999","journal-title":"Nephron"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0405","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1523-1755.1999.055003821.x","article-title":"22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure","volume":"55","author":"Monier-Faugere","year":"1999","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0410","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/1381612003400416","article-title":"Mechanisms for the selective actions of vitamin D analogues","volume":"6","author":"Brown","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0415","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0425","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(00)70198-3","article-title":"Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism","volume":"35","author":"Tsukamoto","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0430","first-page":"67","article-title":"Hectorol: A new vitamin D prohormone","volume":"27","author":"Peter","year":"2000","journal-title":"Nephrol Nurs J"},{"issue":"Suppl","key":"10.1046\/j.1523-1755.2002.00450.x_bb0435","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1053\/ajkd.2001.27425","article-title":"Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients","volume":"38","author":"Akizawa","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0440","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0445","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0149-2918(00)88299-5","article-title":"Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0450","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0455","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0460","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0465","first-page":"2156","article-title":"Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum","volume":"83","author":"Mawer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0470","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0006-2952(97)00004-X","article-title":"Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol","volume":"53","author":"Knutson","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0475","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1\u03b1 hydroxyvitamin D2) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000420167","article-title":"The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion","volume":"91","author":"Nishii","year":"1991","journal-title":"Contrib Nephrol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0485","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ki.1993.83","article-title":"Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism","volume":"43","author":"Finch","year":"1993","journal-title":"Kidney Int"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0490","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/endo.133.3.8396012","article-title":"The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine","volume":"133","author":"Brown","year":"1993","journal-title":"Endocrinology"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0495","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/11.supp3.121","article-title":"Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study","volume":"11","author":"Kurokawa","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0500","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/bi00001a045","article-title":"Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression","volume":"34","author":"Sasaki","year":"1995","journal-title":"Biochemistry"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0960-0760(99)00112-0","article-title":"Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells","volume":"70","author":"Imanishi","year":"1999","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0510","first-page":"200","article-title":"Structure-function relationships in the vitamin D endocrine system","volume":"16","author":"Bouillon","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0515","doi-asserted-by":"crossref","first-page":"16838","DOI":"10.1074\/jbc.274.24.16838","article-title":"20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor","volume":"274","author":"Yang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0520","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/MCB.19.2.1049","article-title":"Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog","volume":"19","author":"Takeyama","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1046\/j.1523-1755.2002.00450.x_bb0525","first-page":"1206","article-title":"Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists","volume":"57","author":"Herdick","year":"2000","journal-title":"Mol Pharmacol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815485631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815485631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T07:16:14Z","timestamp":1622099774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815485631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["S0085253815485631"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00450.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}